<- Go Home
Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
Market Cap
$4.1M
Volume
669.1K
Cash and Equivalents
$6.5M
EBITDA
-$8.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$25.26
52 Week Low
$0.70
Dividend
N/A
Price / Book Value
1.53
Price / Earnings
-0.09
Price / Tangible Book Value
1.53
Enterprise Value
-$2.5M
Enterprise Value / EBITDA
0.29
Operating Income
-$8.5M
Return on Equity
270.02%
Return on Assets
-50.98
Cash and Short Term Investments
$6.5M
Debt
N/A
Equity
$2.7M
Revenue
N/A
Unlevered FCF
-$6.5M
Sector
Biotechnology
Category
N/A